Semaglutide (Ozempic) Linked to Lower Fracture Risk Despite Weight Loss
Patients with type 2 diabetes taking semaglutide—sold as Ozempic, Wegovy, or Rybelsus—showed a 15% lower risk of bone fractures compared to those on other weight-loss medications, according to research presented at the Endocrine Society’s ENDO 2026 meeting. While rapid weight loss is often linked to bone density concerns, this retrospective study of over 59,000 patients … Read more